The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

January 16, 2025

Study Completion Date

January 23, 2025

Conditions
ObesityHeart Failure
Interventions
DRUG

Empagliflozin 10 MG

Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days

DRUG

Placebo

Placebo matches the active drug in appearance, odor and labelling.

Trial Locations (2)

2730

Herlev Hospital, Herlev

5000

Odense University Hospital, Odense

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Danish Heart Foundation

OTHER

collaborator

Herlev and Gentofte Hospital

OTHER

collaborator

University Hospital Bispebjerg and Frederiksberg

OTHER

collaborator

Hillerod Hospital, Denmark

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

Jacob Moller

OTHER